American Association for Cancer Research, Clinical Cancer Research, 2(24), p. 256-258, 2018
DOI: 10.1158/1078-0432.ccr-17-2989
Full text: Unavailable
Abstract Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue, and revisiting drugs with a focus on brain tumor penetration may yield surprises. Clin Cancer Res; 24(2); 256–8. ©2017 AACR. See related article by Byron et al., p. 295